scholarly journals Antibody levels against Streptococcus pneumoniae and Haemophilus influenzae type b in a population of splenectomized individuals with varying vaccination status

1997 ◽  
Vol 119 (2) ◽  
pp. 167-174 ◽  
Author(s):  
H. B. KONRADSEN ◽  
C. RASMUSSEN ◽  
P. EJSTRUD ◽  
J. B. HANSEN
Keyword(s):  
Streptococcus Pneumoniae ◽  
Haemophilus Influenzae ◽  
Vaccine Coverage ◽  
Pneumococcal Vaccination ◽  
Haemophilus Influenzae Type ◽  
Type B ◽  
Serious Infections ◽  
Antibody Levels

In order to determine antibody levels against Streptococcus pneumoniae (pneumococcus) and Haemophilus influenzae type b (Hib) in a population of splenectomized subjects, 561 persons in a Danish county, splenectomized between 1984 and 1993 were identified. Two hundred and thirty-five were alive and 149 participated in the study. Each person donated a blood sample for antibody determination by ELISA. Though vaccine coverage among the 149 persons was 91% only 52% had ‘protective’ levels of pneumococcal antibodies. Despite recommendations for regular follow-up on pneumococcal antibody levels this had only been carried out in 4% of the subjects. Splenectomized subjects who needed pneumococcal revaccination were significantly more likely to have received their initial vaccination less than 14 days before or after splenectomy, as recommended, than those not requiring revaccination. Therefore, the timing of initial pneumococcal vaccination in relation to splenectomy seems to be important. All persons had Hib antibody levels higher than 0·15 μg/ml and 60% had levels higher than 1 μg/ml, which are the levels thought to provide short term and long term protection, respectively. In total, 37% of the 149 persons tested had pneumococcal and Hib antibody levels thought to correlate with protection from serious infections.

Follow-Up of Cases of Haemophilus influenzae Type b Meningitis to Determine Its Long-Term Sequelae

2013 ◽  
Vol 163 (1) ◽  
pp. S44-S49 ◽  
Author(s):  
A.S.M. Nawshad Uddin Ahmed ◽  
Naila Z. Khan ◽  
Manzoor Hussain ◽  
M. Ruhul Amin ◽  
Mohammed Hanif ◽  
...  
Keyword(s):  
Haemophilus Influenzae ◽  
Haemophilus Influenzae Type ◽  
Haemophilus Influenzae Type B ◽  
Type B

Extended follow-up of antibody levels and antigen responsiveness after 2 Haemophilus influenzae type b conjugate vaccines

1999 ◽  
Vol 135 (2) ◽  
pp. 240-245 ◽  
Author(s):  
David W. Scheifele ◽  
Scott A. Halperin ◽  
Roland Guasparini ◽  
William Meekison ◽  
Carolyn Pim ◽  
...  
Keyword(s):  
Haemophilus Influenzae ◽  
Haemophilus Influenzae Type ◽  
Haemophilus Influenzae Type B ◽  
Type B ◽  
Conjugate Vaccines ◽  
Antibody Levels

scholarly journals Characterization of Antibodies to Capsular Polysaccharide Antigens of Haemophilus influenzae Type b and Streptococcus pneumoniae in Human Immune Globulin Intravenous Preparations

2004 ◽  
Vol 11 (6) ◽  
pp. 1158-1164 ◽  
Author(s):  
Malgorzata G. Mikolajczyk ◽  
Nelydia F. Concepcion ◽  
Theresa Wang ◽  
Douglas Frazier ◽  
Basil Golding ◽  
...  
Keyword(s):  
Streptococcus Pneumoniae ◽  
Haemophilus Influenzae ◽  
Immune Globulin ◽  
Haemophilus Influenzae Type ◽  
Enzyme Linked Immunosorbent Assay ◽  
Capsular Polysaccharides ◽  
Type B ◽  
Opsonic Activity ◽  
Antibody Titers ◽  
Antibody Levels

ABSTRACT The most common infections in primary immune deficiency disease (PIDD) patients involve encapsulated bacteria, mainly Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae (pneumococcus). Thus, it is important to know the titers of Hib- and pneumococcus-specific antibodies that are present in immune globulin (Ig) intravenous (IGIV) preparations used to treat PIDD. In this study, seven IGIV preparations were tested by enzyme-linked immunosorbent assay and opsonophagocytic activity for antibody titers to the capsular polysaccharides of Hib and five pneumococcal serotypes. Differences in Hib- and pneumococcus-specific antibody titer were observed among various IGIV preparations, with some products having higher- or lower-than-average titers. Opsonic activity also varied among preparations. As expected, IgG2 was the most active subclass of both binding and opsonic activity except against pneumococcal serotype 6B where IgG3 was the most active. This study determines antibody titers against capsular polysaccharides of Hib and pneumococcus in seven IGIV products that have been shown to be effective in reducing infections in PIDD patients. As donor antibody levels and manufacturing methods continue to change, it may prove useful from a regulatory point of view to reassess IGIV products periodically, to ensure that products maintain antibody levels that are important for the health of IGIV recipients.

Epidemiology of Haemophilus Type B Invasive Disease in Childhood in Glasgow

1993 ◽  
Vol 38 (1) ◽  
pp. 18-20 ◽  
Author(s):  
A Coggins ◽  
C.W. Shepherd ◽  
F. Cockburn
Keyword(s):  
Haemophilus Influenzae ◽  
Invasive Disease ◽  
Annual Incidence ◽  
Childhood Vaccination ◽  
Haemophilus Influenzae Type ◽  
Haemophilus Influenzae Type B ◽  
Type B ◽  
Neurological Sequelae ◽  
The United Kingdom

The objective of this study was to investigate the epidemiology of invasive disease due to Haemophilus influenzae type b in childhood in Glasgow. A retrospective study has been made on the hospital records of 252 children aged 0 to 12 years admitted to Glasgow hospitals during 1981–1990. The annual incidence of invasive Haemophilus influenzae type b disease in Glasgow was estimated at 39 per 100,000 children less than five years of age per year. The figure for Haemophilus meningitis was 23.8 per 100,000 children less than five years of age per year. Ninety-five per cent of all cases occurred in children less than five years of age and 72.1% of meningitis cases occurred before two years of age. There was a mortality of 2.77%. Long-term neurological sequelae were found in 15.3% of the survivors. The annual incidence of Haemophilus influenzae type b disease is slightly higher in Glasgow than previously reported for the United Kingdom. The study provides baseline data to help assess efficacy of proposed early childhood vaccination.

Moxalactam Treatment of Serious Infections Primarily Due to Haemophilus influenzae Type b in Children

PEDIATRICS ◽  
1983 ◽  
Vol 71 (2) ◽  
pp. 187-191
Author(s):  
Sheldon L. Kaplan ◽  
Edward O. Mason ◽  
Sally J. Kvernland ◽  
Elaine M. Loiselle ◽  
Ralph D. Feigin
Keyword(s):  
Haemophilus Influenzae ◽  
Adverse Reactions ◽  
Etiologic Agent ◽  
Haemophilus Influenzae Type ◽  
Haemophilus Influenzae Type B ◽  
Type B ◽  
Cns Infections ◽  
Serious Infections ◽  
Resistant Strains ◽  
Transient Elevation

Thirty-eight children completed therapy with moxalactam for a variety of non-CNS infections. Haemophilus influenzae type b (seven ampicillin-resistant strains) was the etiologic agent for 32 children. Doses of moxalactam ranged from 113 to 200 mg/kg/d in three or four divided doses administered parenterally. All children with infections due to H influenzae type b had excellent responses to moxalactam therapy. Children treated for infections due to other agents also responded satisfactorily to moxalactam therapy. Moxalactam concentrations in joint and pleural fluids greatly exceeded the minimal bactericidal concentrations of moxalactam for H influenzae type b. Adverse reactions included neutropenia, eosinophilia, thrombocytosis, and transient elevation of transaminase levels. Moxalactam administered parenterally, at a dose of 113 to 150 mg/kg/d in three or four divided doses is effective therapy for serious infections in children due to H influenzae type b and selected other organisms.

Sign in / Sign up

Export Citation Format

Share Document